| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.73B | 5.64 | 58.02 | 43.5% | 9.32% | 1.89% | ||
| CORTCorcept Therapeutics Incorporated | 3.82B | 36.35 | 29.55 | 39.94% | 14.19% | 16.65% | 5.12% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 308.28M | 2.01 | -1.24 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 436.08M | 1.20 | -1.90 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 229.96M | 2.48 | -2.53 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 164.38M | 1.93 | -2.88 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 418.41M | 4.01 | -2.99 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 741.84M | 20.69 | -3.12 | -12.81% | -27.32% | 0.03 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.64M | 5.23M | 41.5K | 10.33M | 5.8M | 8.19M | 4.41M | -68K | 426K | 20K |
| Revenue Growth % | 0.04% | -0.51% | -0.99% | 247.93% | -0.44% | 0.41% | -0.46% | -1.02% | 7.26% | -0.95% |
| Cost of Goods Sold | 5.06M | 7.22M | 18.41M | 18.46M | 0 | 33.51M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 0.48% | 1.38% | 443.49% | 1.79% | - | 4.09% | - | - | - | - |
| Gross Profit | 5.58M | -1.99M | -18.36M | -8.13M | 5.8M | -25.32M | 4.41M | -68K | 426K | 20K |
| Gross Margin % | 0.52% | -0.38% | -442.49% | -0.79% | 1% | -3.09% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | -0.06% | -1.36% | -8.22% | 0.56% | 1.71% | -5.37% | 1.17% | -1.02% | 7.26% | -0.95% |
| Operating Expenses | 11.5M | 16.49M | 16.17M | 28.22M | 27.27M | 29.47M | 101.32M | 87.67M | 96.36M | 103.19M |
| OpEx % of Revenue | 1.08% | 3.15% | 389.54% | 2.73% | 4.7% | 3.6% | 22.98% | -1289.29% | 226.19% | 5159.6% |
| Selling, General & Admin | 6.22M | 11.52M | 8.46M | 9.77M | 8.5M | 13.21M | 15.41M | 17.13M | 18.14M | 20.97M |
| SG&A % of Revenue | 0.58% | 2.2% | 203.78% | 0.95% | 1.47% | 1.61% | 3.5% | -251.97% | 42.58% | 1048.3% |
| Research & Development | 5.13M | 4.84M | 18.41M | 18.46M | 17.77M | 49.77M | 74.54M | 70.54M | 65.8M | 82.23M |
| R&D % of Revenue | 0.48% | 0.92% | 443.49% | 1.79% | 3.06% | 6.08% | 16.9% | -1037.32% | 154.46% | 4111.3% |
| Other Operating Expenses | 8.14K | 7.85K | 5.67K | 277.89K | 1M | -33.51M | 11.37M | 0 | 12.42M | 0 |
| Operating Income | -3.4M | -11.26M | -52.05M | -42.83M | -21.46M | -54.8M | -96.91M | -87.74M | -95.93M | -103.17M |
| Operating Margin % | -0.32% | -2.15% | -1254.01% | -4.15% | -3.7% | -6.69% | -21.98% | 1290.29% | -225.19% | -5158.6% |
| Operating Income Growth % | 0.67% | -2.31% | -3.62% | 0.18% | 0.5% | -1.55% | -0.77% | 0.09% | -0.09% | -0.08% |
| EBITDA | -3.26M | -11.13M | -51.91M | -42.53M | -21.08M | -54.37M | -96.36M | -87.25M | -95.45M | -102.93M |
| EBITDA Margin % | -0.31% | -2.13% | -1250.66% | -4.12% | -3.63% | -6.64% | -21.85% | 1283.04% | -224.07% | -5146.7% |
| EBITDA Growth % | 0.68% | -2.41% | -3.66% | 0.18% | 0.5% | -1.58% | -0.77% | 0.09% | -0.09% | -0.08% |
| D&A (Non-Cash Add-back) | 141.6K | 135.34K | 139.02K | 302.37K | 387.32K | 428.88K | 551K | 493K | 477K | 238K |
| EBIT | -856.64K | -11.05M | -51.9M | -45.02M | -20.58M | -38.53M | -97.08M | -84.9M | -88.41M | -95.05M |
| Net Interest Income | -54.58K | -37.45K | -114.56K | -70.49K | 841.16K | 313.09K | 198K | 2.86M | 7.32M | 8.06M |
| Interest Income | 0 | 1.05K | 47.58K | 226.6K | 843.41K | 322.51K | 203K | 2.87M | 7.35M | 8.07M |
| Interest Expense | 54.58K | 38.5K | 162.14K | 297.09K | 2.24K | 9.42K | 5K | 8K | 35K | 9K |
| Other Income/Expense | 3.21M | 4.85K | -18.51K | -2.49M | 886.3K | 11.17M | -176K | 2.83M | 7.48M | 8.11M |
| Pretax Income | -3.38M | 205.02M | -52.06M | -45.32M | -20.58M | -43.63M | -97.09M | -84.91M | -88.45M | -95.06M |
| Pretax Margin % | -0.32% | 39.2% | -1254.46% | -4.39% | -3.55% | -5.33% | -22.02% | 1248.68% | -207.62% | -4752.95% |
| Income Tax | 61.75K | 11.17M | -5.64M | -6.15M | -58.5K | 5.42M | 0 | -197K | 0 | 0 |
| Effective Tax Rate % | 1.02% | 0.95% | 0.89% | 0.86% | 1% | 1.12% | 1% | 1% | 1% | 1% |
| Net Income | -3.44M | 193.85M | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M |
| Net Margin % | -0.32% | 37.06% | -1118.6% | -3.79% | -3.54% | -5.99% | -22.02% | 1245.78% | -207.62% | -4752.95% |
| Net Income Growth % | 0.65% | 57.34% | -1.24% | 0.16% | 0.48% | -1.39% | -0.98% | 0.13% | -0.04% | -0.07% |
| Net Income (Continuing) | -3.44M | -11.09M | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -16.13 | -49.80 | -108.77 | -13.98 | -1.56 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 |
| EPS Growth % | 0.69% | -2.09% | -1.18% | 0.87% | 0.89% | -0.22% | -0.23% | 0.23% | 0.08% | 0.19% |
| EPS (Basic) | -16.13 | -49.80 | -108.77 | -13.98 | -1.56 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 |
| Diluted Shares Outstanding | 213.28K | 230.38K | 426.83K | 2.8M | 13.12M | 25.64M | 41.28M | 46.93M | 53.25M | 71M |
| Basic Shares Outstanding | 213.28K | 230.38K | 426.83K | 2.8M | 13.12M | 25.64M | 41.28M | 46.93M | 53.25M | 71M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.23M | 222.27M | 23.47M | 39.37M | 39.39M | 230.26M | 204.13M | 192.81M | 209.63M | 137.25M |
| Cash & Short-Term Investments | 15.57M | 220.81M | 8.77M | 33.72M | 37.24M | 215.92M | 190.3M | 184.88M | 197.81M | 131.89M |
| Cash Only | 15.57M | 153.99M | 8.77M | 33.72M | 8.96M | 115.92M | 190.3M | 111.1M | 135.12M | 36.93M |
| Short-Term Investments | 0 | 66.81M | 0 | 0 | 28.28M | 100.01M | 0 | 73.78M | 62.7M | 94.97M |
| Accounts Receivable | 1.48M | 999.14K | 10.17M | 4.47M | 1.65M | 12.37M | 5.84M | 2.54M | 4.85M | 3.12M |
| Days Sales Outstanding | 50.61 | 69.73 | 89.42K | 157.96 | 103.83 | 551.76 | 483.27 | -13.64K | 4.16K | 56.89K |
| Inventory | 0 | 0 | 3.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 70.08 | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 807.51K | 3.53M | 634.42K | 34.17K | 34.17K | 33.31K | 5.39M | 6.96M | 2.25M |
| Total Non-Current Assets | 2.64M | 2.47M | 39.56M | 15.38M | 14.66M | 14.86M | 14.74M | 14.12M | 1.01M | 2.05M |
| Property, Plant & Equipment | 233.69K | 120.94K | 603.15K | 1.34M | 1.8M | 1.96M | 1.45M | 1.08M | 651K | 413K |
| Fixed Asset Turnover | 45.53x | 43.24x | 0.07x | 7.69x | 3.22x | 4.17x | 3.05x | -0.06x | 0.65x | 0.05x |
| Goodwill | 22.49M | 18.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 17.82M | 14.95M | 38.72M | 13.85M | 12.73M | 12.82M | 12.42M | 12.42M | 0 | 0 |
| Long-Term Investments | 0 | 0 | -5.94B | -58.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 53.38K | 0 | 238.92K | 183.68K | 128.55K | 73.41K | 872K | 615K | 363K | 1.64M |
| Total Assets | 19.86M | 224.74M | 63.03M | 54.75M | 54.06M | 245.12M | 218.87M | 206.93M | 210.64M | 139.31M |
| Asset Turnover | 0.54x | 0.02x | 0.00x | 0.19x | 0.11x | 0.03x | 0.02x | -0.00x | 0.00x | 0.00x |
| Asset Growth % | -0.1% | 10.31% | -0.72% | -0.13% | -0.01% | 3.53% | -0.11% | -0.05% | 0.02% | -0.34% |
| Total Current Liabilities | 2.18M | 204.84M | 3.84M | 4.53M | 3.92M | 12.02M | 18.28M | 17.05M | 12.14M | 10.47M |
| Accounts Payable | 521.12K | 2.01M | 129.07K | 372.86K | 18.23K | 612.29K | 2.03M | 4.8M | 2.07M | 211K |
| Days Payables Outstanding | 37.56 | 101.35 | 2.56 | 7.37 | - | 6.67 | - | - | - | - |
| Short-Term Debt | 0 | 458.63K | 49.7K | 71.6K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -537.74K | 19.75K | 19.75K | 19.75K | 61.56K | 19.75K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 955.3K | 620.59K | 1.9M | 2.81M | 0 | 8.68M | 6.09M | 0 | 0 | 0 |
| Current Ratio | 7.90x | 1.09x | 6.11x | 8.70x | 10.04x | 19.16x | 11.17x | 11.31x | 17.26x | 13.11x |
| Quick Ratio | 7.90x | 1.09x | 5.19x | 8.70x | 10.04x | 19.16x | 11.17x | 11.31x | 17.26x | 13.11x |
| Cash Conversion Cycle | - | - | 89.49K | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.03M | 442.59K | 10.51M | 1.91M | 4.61M | 7.22M | 1.45M | 4.58M | 4.4M | 5.33M |
| Long-Term Debt | 0 | 525.95K | 599.93K | 501.17K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.48M | 1.47M | 1.12M | 672K | 175K | 1.4M |
| Deferred Tax Liabilities | 0 | -705.37K | 5.94M | 58.5K | 0 | -250K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.03M | 16.91K | 3.81M | 1.35M | 2.88M | 5.75M | 330K | 3.91M | 4.22M | 3.93M |
| Total Liabilities | 3.21M | 205.28M | 14.35M | 6.44M | 8.54M | 19.24M | 19.73M | 21.64M | 16.54M | 15.8M |
| Total Debt | 1.08M | 984.58K | 49.7K | 572.77K | 1.74M | 1.82M | 1.53M | 1.12M | 671K | 1.68M |
| Net Debt | -14.49M | -153.01M | -8.72M | -33.15M | -7.22M | -114.09M | -188.77M | -109.97M | -134.45M | -35.24M |
| Debt / Equity | 0.07x | 0.05x | 0.00x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -62.34x | -292.59x | -320.99x | -144.18x | -9565.48x | -5816.66x | -19382.80x | -10967.50x | -2740.83x | -11463.56x |
| Total Equity | 16.65M | 19.46M | 48.68M | 48.31M | 45.52M | 225.88M | 199.13M | 185.29M | 194.1M | 123.51M |
| Equity Growth % | -0.09% | 0.17% | 1.5% | -0.01% | -0.06% | 3.96% | -0.12% | -0.07% | 0.05% | -0.36% |
| Book Value per Share | 78.06 | 84.46 | 114.04 | 17.24 | 3.47 | 8.81 | 4.82 | 3.95 | 3.65 | 1.74 |
| Total Shareholders' Equity | 16.65M | 19.46M | 48.68M | 48.31M | 45.52M | 225.88M | 199.13M | 185.29M | 194.1M | 123.51M |
| Common Stock | 6.44K | 6.77K | 1.81K | 876 | 1.51K | 3.7K | 4K | 5K | 7K | 7K |
| Retained Earnings | -223.72M | -29.87M | -77.68M | -116.86M | -137.38M | -186.42M | -293.17M | -377.88M | -466.33M | -561.39M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.86M | -1.05K | -4.58M | -5.04M | -5.02M | -5.04M | -5.04M | -5.23M | -5M | -4.97M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.22M | 201.51M | -20.21M | -9.39M | -9.6M | -34.31M | -78.24M | -62.59M | -75.81M | -79.85M |
| Operating CF Margin % | -0.3% | 38.53% | -487.05% | -0.91% | -1.66% | -4.19% | -17.74% | 920.38% | -177.96% | -3992.4% |
| Operating CF Growth % | 0.62% | 63.66% | -1.1% | 0.54% | -0.02% | -2.57% | -1.28% | 0.2% | -0.21% | -0.05% |
| Net Income | -3.44M | 193.85M | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M |
| Depreciation & Amortization | 141.6K | 143.44K | 139.02K | 302.37K | 387.32K | 428.88K | 551K | 493K | 477K | 238K |
| Stock-Based Compensation | 613.02K | 2.24M | 1.44M | 773.25K | 0 | 2.58M | 5.52M | 8.1M | 10.64M | 14.39M |
| Deferred Taxes | 61.75K | 61.82K | -2.62B | -6.15M | -58.5K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -86.26K | 1.01M | 2.65B | 27.88M | 8.77M | 16.25M | 13.03M | -578K | 9.79M | -3.9M |
| Working Capital Changes | -505.38K | 4.2M | -11.31M | 6.98M | 1.82M | -4.51M | -251K | 14.11M | -8.27M | 4.48M |
| Change in Receivables | -1.07M | 476.19K | -1.95M | 344.3K | 2.82M | -10.72M | 6.53M | 3.3M | -2.31M | 1.74M |
| Change in Inventory | -14.62M | 3.27M | -4.12M | 5.59M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 129.73K | 405.41K | -2.62M | 243.06K | -354.63K | 594.06K | 1.42M | 2.77M | -2.73M | -1.86M |
| Cash from Investing | -78.91K | -66.88M | 13.73M | -1M | -28.29M | -72.23M | 87.52M | -73.4M | 13.73M | -28.39M |
| Capital Expenditures | -86.51K | -30.69K | -166.33K | -1.02M | -29K | -203.96K | -12.12M | -126K | -47K | 0 |
| CapEx % of Revenue | 0.01% | 0.01% | 4.01% | 0.1% | 0% | 0.02% | 2.75% | -1.85% | 0.11% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 7.6K | 687 | 207.63K | 14.49K | 0 | -138.46K | -195K | 0 | 0 | 0 |
| Cash from Financing | 223.13K | 3.8M | 15.84M | 32.49M | 12.53M | 213.49M | 65.1M | 56.78M | 86.11M | 10.04M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -611.65K | 16.45K | -977.1K | 125K | 41.17M | 58K | 434K | -496K | 50K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -3.3M | 201.48M | -20.38M | -10.4M | -9.6M | -34.65M | -90.55M | -62.71M | -75.86M | -79.85M |
| FCF Margin % | -0.31% | 38.52% | -491.06% | -1.01% | -1.66% | -4.23% | -20.53% | 922.24% | -178.07% | -3992.4% |
| FCF Growth % | 0.61% | 62.01% | -1.1% | 0.49% | 0.08% | -2.61% | -1.61% | 0.31% | -0.21% | -0.05% |
| FCF per Share | -15.48 | 874.54 | -47.75 | -3.71 | -0.73 | -1.35 | -2.19 | -1.34 | -1.42 | -1.12 |
| FCF Conversion (FCF/Net Income) | 0.93x | 1.04x | 0.44x | 0.24x | 0.47x | 0.70x | 0.81x | 0.74x | 0.86x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 1.79K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -19.7% | 1073.74% | -136.27% | -80.77% | -43.74% | -36.14% | -45.69% | -44.07% | -46.63% | -59.86% |
| Return on Invested Capital (ROIC) | -201.01% | - | -97.69% | -116.56% | -60.22% | -54.77% | -119.01% | -153.59% | -106.61% | -104.63% |
| Gross Margin | 52.41% | -38.07% | -44249.39% | -78.68% | 100% | -309.4% | 100% | 100% | 100% | 100% |
| Net Margin | -32.34% | 3706.44% | -111860.32% | -379.16% | -353.71% | -599.2% | -2201.59% | 124577.94% | -20762.21% | -475295% |
| Debt / Equity | 0.07x | 0.05x | 0.00x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x |
| Interest Coverage | -62.34x | -292.59x | -320.99x | -144.18x | -9565.48x | -5816.66x | -19382.80x | -10967.50x | -2740.83x | -11463.56x |
| FCF Conversion | 0.93x | 1.04x | 0.44x | 0.24x | 0.47x | 0.70x | 0.81x | 0.74x | 0.86x | 0.84x |
| Revenue Growth | 4.42% | -50.85% | -99.21% | 24792.58% | -43.85% | 41.09% | -46.12% | -101.54% | 726.47% | -95.31% |
| 2018 | 2020 | 2021 | |
|---|---|---|---|
| Grant | 10.31M | 3.1M | 3.7M |
| Grant Growth | - | -69.94% | 19.35% |
| License And Service | 19.78K | - | - |
| License And Service Growth | - | - | - |
Altimmune, Inc. (ALT) reported $0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $24.3M in 2011.
Altimmune, Inc. (ALT) saw revenue decline by 95.3% over the past year.
Altimmune, Inc. (ALT) reported a net loss of $83.9M for fiscal year 2024.
Altimmune, Inc. (ALT) has a return on equity (ROE) of -59.9%. Negative ROE indicates the company is unprofitable.
Altimmune, Inc. (ALT) had negative free cash flow of $66.7M in fiscal year 2024, likely due to heavy capital investments.